Your browser doesn't support javascript.
loading
[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma].
Yang, Xue-Liang; Wu, Ya-Mei; Cao, Yong-Bin; Li, Xiao-Hong; Xu, Li-Xin; Liu, Zhou-Yang; Liu, Bei; Yan, Bei; Li, Song-Wei; DA, Wan-Ming; Wu, Xiao-Xiong.
Afiliación
  • Yang XL; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Wu YM; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Cao YB; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Li XH; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Xu LX; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Liu ZY; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Liu B; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Yan B; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • Li SW; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
  • DA WM; Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
  • Wu XX; Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China. E-mail: xiongwuxiao@sohu.com.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 24(6): 1743-1747, 2016 Dec.
Article en Zh | MEDLINE | ID: mdl-28024487
ABSTRACT

OBJECTIVE:

To investigate the safety and effectiveness of autologous hematopoietic stem cell transplantation (auto-HSCT) using tumor-ablative conditioning regiment for patients with refractory/relapsed non-Hodgkin's lymphoma.

METHODS:

The clinical data of 16 patients with refractory/relapsed non-Hodgkin's lymphoma received above-mentioned therapeutic regimen from January 2013 to July 2015 was analyzed retrospectively, and conditioning-related toxicity, engraftment, infection, relapse and survival rate were evaluated.

RESULTS:

No conditioning-related organs' failure and mortality were found. Only 1 patient had not been engrafted, and the engraftment rate was 93.7%. The incidence of serious infection was 31.2%. The median follow-up was 20.5(1-30) months, and 3 patients died, out of them 2 patients died of relapse. Two year overall survival (OS) , disease-free survival (DFS) and relapse rates were 80.2%, 74.5% and 20.6% respectively.

CONCLUSION:

Auto-HSCT using tumor-ablative conditioning regimen is safe and effective for patients with refractory/relapsed non-Hodgkin's lymphoma, and it possess a certain effect for reducing disease relapse after transplantation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Homólogo / Linfoma no Hodgkin / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Homólogo / Linfoma no Hodgkin / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: China
...